The Hidden Cost of Weight Loss Meds: Reevaluating Muscle, Metabolism, and Modern Obesity Treatments

Échec de l'ajout au panier.

Veuillez réessayer plus tard

Échec de l'ajout à la liste d'envies.

Veuillez réessayer plus tard

Échec de la suppression de la liste d’envies.

Veuillez réessayer plus tard

Échec du suivi du balado

Ne plus suivre le balado a échoué

The Hidden Cost of Weight Loss Meds: Reevaluating Muscle, Metabolism, and Modern Obesity Treatments

Écouter gratuitement

Voir les détails du balado

À propos de cet audio

Current and emergent incretin-based therapies (such as GLP-1 and GIP receptor agonists) have transformed obesity treatment by producing unprecedented weight loss. But these benefits come with complexity: significant lean mass loss, raising concerns about metabolic stability, muscle health, and long-term outcomes. In this episode, we briefly revisit the clinical approach to weight-loss medications, connect the foundations of leptin dysregulation with leptin-independent pathways (including the activin/follistatin/myostatin/IGF-1 system), and link these pathways to energy homeostasis and muscle maintenance. We also discuss strategies to preserve lean mass during significant pharmacologically-induced weight reduction.

Pas encore de commentaire